The Merck Group's first-quarter 2012 total revenues rose 3.2% to € 2,645 million compared to € 2,564 million in the first quarter of 2011. Sales for the Group increased 3.5% to € 2,564 million in first quarter compared to € 2,478 million in the year-ago quarter. This performance reflected organic sales growth of 1.2%, a 1.7% positive benefit from changes in foreign exchange rates and a 0.6% boost from acquisitions and divestments. The Group’s organic sales growth was entirely driven by the Merck Serono and Merck Millipore divisions during the quarter.
Abbott (NYSE: ABT) today announced that the XIENCE PRIME™ and the XIENCE V® Everolimus Eluting Coronary Stent Systems have received CE Mark in Europe for the use of dual anti-platelet therapy (DAPT) for at least three months after stent implantation in patients with coronary artery disease. This is the shortest duration of DAPT for any major drug eluting stent (DES) in Europe.
GSK issued the following statement in response to the BBC Panorama programme related to Corporation Tax payments in the UK and Luxembourg broadcast tonight, Monday 14 May 2012. "GSK is very disappointed with this programme which was extremely misleading and lacking in context. Specifically, the programme's selective use of facts led to a misrepresentation of GSK's actions and a failure to recognize GSK's significant UK tax contribution.|
Global pharma companies are missing a chance to serve Brazil’s increasingly prosperous and growing middle class. Read more on the McKinsey Quarterly > |
Topics:
|
|
The country may well foster new models of innovation, but success will require a long-term commitment and talent development. Read more on the McKinsey Quarterly > |
Topics:
|
|
Dynamic domestic players and focused multinationals are helping China churn out a growing number of innovative products and services. Intensifying competition lies ahead; here’s a road map for navigating it. Read more on the McKinsey Quarterly > |
Topics:
|